ReviewPLoS pathogens2018
HIV control: Is getting there the same as staying there?
Review in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 73 citations in OpenAlex.
- Post-treatment SIV control is associated with specific features of viral persistence before and after treatment interruption.Nature communications · 2026Article
- A genetic fingerprint associated with durable HIV remission after interruption of antiretroviral treatment: ANRS VISCONTI/PRIMO.Med (New York, N.Y.) · 2025Article
- High peak viraemia followed by spontaneous HIV-1 control in women living with HIV-1 subtype A1 in East Africa.Journal of the International AIDS Society · 2025Article
- Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children.Current opinion in HIV and AIDS · 2025Review
- Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.Vaccines · 2025Review
- Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission.Nature medicine · 2024Article
- Antiviral capacity of the early CD8 T-cell response is predictive of natural control of SIV infection: Learning in vivo dynamics using ex vivo data.PLoS computational biology · 2024Article
- Modelling HIV-1 control and remission.NPJ systems biology and applications · 2024Review
- Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8Nature communications · 2024Article
- Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART.Frontiers in immunology · 2024Article
- Acute-phase innate immune responses in SIVmac239-infectedFrontiers in immunology · 2024Article
- Multiplex interrogation of the NK cell signalome reveals global downregulation of CD16 signaling during lentivirus infection through an IL-18/ADAM17-dependent mechanism.PLoS pathogens · 2023Article
- Antiretroviral therapy restores the homeostatic state of microglia in SIV-infected rhesus macaques.Journal of leukocyte biology · 2022Article
- Elite controllers long-term non progressors present improved survival and slower disease progression.Scientific reports · 2022Article
- Article
- Transmitted HIV-1 is more virulent in heterosexual individuals than men-who-have-sex-with-men.PLoS pathogens · 2022Article
- Findings From Mayo Clinic's Post-COVID Clinic: PASC Phenotypes Vary by Sex and Degree of IL-6 Elevation.Mayo Clinic proceedings · 2022Article
- Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry.Nature communications · 2022Article
- Learning to Be Elite: Lessons From HIV-1 Controllers and Animal Models on Trained Innate Immunity and Virus Suppression.Frontiers in immunology · 2022Review
- Morphine suppresses peripheral responses and transforms brain myeloid gene expression to favor neuropathogenesis in SIV infection.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
In this brief review and perspective, we address the question of whether the immune responses that bring about immune control of acute HIV infection are the same as, or distinct from, those that maintain long-term viral suppression once control of viremia has been achieved. To this end, we describe the natural history of elite and post-treatment control, noting the lack of data regarding what happens acutely. We review the evidence suggesting that the two clinical phenotypes may differ in terms of the mechanisms required to achieve and maintain control, as well as the level of inflammation that persists once a steady state is achieved. We then describe the evidence from longitudinal studies of controllers who fail and studies of biologic sex (male versus female), age (children versus adults), and simian immunodeficiency virus (SIV) (pathogenic/experimental versus nonpathogenic/natural infection). Collectively, these studies demonstrate that the battle between the inflammatory and anti-inflammatory pathways during acute infection has long-term consequences, both for the degree to which control is maintained and the health of the individual. Potent and stringent control of HIV may be required acutely, but once control is established, the chronic inflammatory response can be detrimental. Interventional approaches designed to bring about HIV cure and/or remission should be nuanced accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.